Clinical Trials Currently Open to Patient Enrollment

Total Therapy 7:  UARK 2015-12– A Phase II Study Exploring the Use of Early and Late Consolidation/Maintenance With Anti-CD38 (Protein) Monoclonal Antibody to Improve Progression Free Survival in Patients With Newly Diagnosed Multiple Myeloma

Principal Investigator:  Dr. Faith Davies Identifier:  NCT03004287

Total Therapy 8:  UARK 2017-03– A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma

Principal Investigator:  Dr. Faith Davies Identifier:  NCT03168100

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Principal Investigator:  Dr. Faith Davies Identifier:  NCT03309111

A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 in Subjects With Multiple Myeloma

Principal Investigator:  Dr. Faith Davies Identifier: NCT03287908

UARK 2016-02:  A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies

Principal Investigator:  Dr. Faith Davies Identifier:  NCT01943851

UARK 2016-09:  A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

Principal Investigator:  Dr. Faith Davies Identifier:  NCT02431208

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma(MM)

Principal Investigator:  Dr. Gareth Morgan Identifier: NCT02899052

An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants

Principal Investigator:  Dr. Faith Davies Identifier:  NCT02761187

A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus

Principal Investigator: Dr. Frits van Rhee Identifier:  NCT02192775

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Principal Investigator: Dr. Faith Davies Identifier:  NCT02034110

Total Therapy 5B: A Phase II Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission (AS-CR) By Applying Non-Host-Exhausting and Timely Dose-Reduced MEL-80-CFZ-TD-PACE Transplant(s) with Interspersed MEL-20-CFZ-TD-PACE with CFZ-RD and CFZ-D Maintenance

Principal Investigator:  Dr. Frits van Rhee Identifier:   NCT02128230

2011-61 A Prospective Observational Study of Patients with Monoclonal Gammopathy (MGUS) and Asymptomatic Multiple Myeloma (AMM)

Principal Investigator:  Dr. Carolina Schinke